Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

November 23, 2020November 23, 2020

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

News, syndicated

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to ... Read more

November 9, 2020November 9, 2020

Oral Therapy Avacopan for AAV Now Under Regulatory Review in Europe

News

The European Medicines Agency (EMA) has agreed to review Vifor Pharma and ChemoCentryx’s application requesting the approval of avacopan to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), ... Read more

September 28, 2020September 28, 2020

B-cells Marker Levels May Predict Complete Responses to Rituximab in GPA, MPA

News

High blood levels of FCRL5 — a protein mainly found in certain B-cells, a type of immune cell — are linked with a greater likelihood of achieving and maintaining ... Read more

June 4, 2020June 4, 2020

Mycophenolate Mofetil May Be Alternative to Cyclophosphamide, Analysis Shows

News

Mycophenolate mofetil (MMF) may be a safe and effective alternative to the standard induction therapy cyclophosphamide in certain ANCA-associated vasculitis (AAV) patients, a review study reports. Based on the data, ... Read more

March 4, 2020March 4, 2020

Lung Involvement Increases Relapse Risk in Chinese Patients With MPO-AAV, Study Says

News

Lung involvement increases the risk for both induction therapy resistance and disease relapse in ANCA-associated vasculitis (AAV) patients with autoantibodies against myeloperoxidase, a Chinese study suggests. High levels of ... Read more

January 15, 2020July 13, 2020

ChemoCentryx Secures $100M Credit to Support Avacopan’s Approval Applications, Potential Commercial Launch

News

ChemoCentryx has secured a credit facility of up to $100 million from Hercules Capital to support the upcoming costs of its new drug application (NDA) for avacopan, its investigational treatment for ANCA-associated vasculitis ... Read more

December 11, 2019December 14, 2019

Mitochondrial DNA May Serve as Urinary Biomarker of Kidney Damage, Chinese Study Suggests

News

Mitochondrial DNA (mtDNA) — DNA specific to mitochondria, the cell’s powerhouses — may be used as a urinary biomarker of kidney damage in people with ANCA-associated vasculitis (AAV), according to ... Read more

November 25, 2019November 26, 2019

Smoking Raises Person’s Risk of AAV, Large US Study Suggests

News

Being a former or current cigarette smoker significantly increases the risk of developing ANCA-associated vasculitis (AAV), data from a large U.S. study show. This association was particularly strong in ... Read more

August 22, 2019

Improved Classification Systems Needed for AAV, Study Shows

News

The autoimmune condition ANCA-associated vasculitis (AAV) needs improved classification systems that can better predict disease outcomes, a Spanish study says. Disease management should be based more on individual patient ... Read more

September 10, 2018

Antiviral Therapy May Reduce Risk of Infection in AAV Patients, Clinical Study Suggests

News

Antiviral therapy prevents silent reactivation of cytomegalovirus (CMV) in ANCA-associated vasculitis (AAV) patients and improves patients’ immune responses, a proof-of-concept clinical study shows. These results suggest that antiviral therapy may reduce ... Read more